26Nov 2021
Cardiovascular risk profiles: A cross‐sectional study evaluating the generalizability of the glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials REWIND, LEADER and SUSTAIN‐6 to the real‐world type 2 diabetes population in the United Kingdom

Cardiovascular risk profiles: A cross‐sectional study evaluating the generalizability of the glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials REWIND, LEADER and SUSTAIN‐6 to the real‐world type 2 diabetes population in the United Kingdom

To determine the proportion of UK patients with type 2 diabetes (T2D) who meet the cardiovascular (CV) or combined CV/core eligibility criteria used for the CV outcome trials (CVOTs) of UK‐marketed glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) showing CV benefit (dulaglutide in REWIND, liraglutide in LEADER and injectable semaglutide in SUSTAIN‐6). Adults with T2D on/before June 2018 were identified from the UK Clinical Practice Research Datalink GOLD primary care database and linked to Hospital Episode Statistics data (Protocol 19_262). Patient CV and clinical data were evaluated against the CVOT eligibility criteria. Data were analysed descriptively. The study cohort (N = 33 118 patients with T2D) had a mean (standard deviation) age of 66.0 (13.3) years and 56.6% were male...

  • #endo-diabetology

Like

Save

Share